文献速递乳腺癌

转移性乳腺癌患者临床结局与循环肿瘤细胞及循环游离DNA的关联

Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA.
PubMed 文献 · Eur J Cancer · 2018-12-04

研究纳入117例转移性乳腺癌患者的227份血样,分析循环肿瘤细胞(CTC)与总循环游离DNA(ccfDNA)对预后影响的单独及联合效应。结果显示CTC≥5个和ccfDNA高水平均与无进展生存期和总生存期显著相关,且两标志物高水平联合时死亡风险增加超过17倍。

要点

  • CTC≥5个的患者疾病进展风险增加2.58倍,死亡风险增加3.63倍。
  • ccfDNA高水平与进展风险增加2.05倍、死亡风险增加3.56倍相关。
  • CTC与ccfDNA均高水平者较两者均低水平者死亡风险增加超过17倍(P < 0.001)。

核心结论

  • 在转移性乳腺癌患者中,CTC与总ccfDNA水平分别及联合与无进展生存期和总生存期相关。

研究设计与样本

  • 研究收集117例转移性乳腺癌患者的227份血样,采用CellSearch系统计数CTC,用定量实时聚合酶链反应和Qubit荧光仪定量ccfDNA,并用Cox比例风险模型分析CTC和ccfDNA水平对无进展生存期和总生存期的单独及联合效应。

主要发现

  • 与CTC<5个的患者相比,CTC≥5个的患者疾病进展风险增加2.58倍,死亡风险增加3.63倍。
  • ccfDNA高水平与疾病进展风险增加2.05倍和死亡风险增加3.56倍相关。
  • 调整其他重要临床协变量及CTC/ccfDNA水平后,上述关联仍显著。
  • 与CTC和ccfDNA均低水平的患者相比,两者均高水平的患者死亡风险增加超过17倍(P < 0.001)。
  • 对22例患者132份样本的纵向分析提示,部分患者CTC水平与结局不一致可能由ccfDNA水平解释。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Both circulating tumour cell (CTC) and total circulating cell-free DNA (ccfDNA) predict cancer patient prognosis. However, no study has explored the prognostic value of the combined use of CTC and ccfDNA. We aimed to investigate individual and joint effects of CTC and ccfDNA on clinical outcomes of metastatic breast cancer (MBC) patients. METHODS: We collected 227 blood samples from 117 MBC patients. CTCs were enumerated using the CellSearch System. ccfDNAs were quantified by quantitative real-time polymerase chain reaction and Qubit fluorometer. The individual and joint effects of CTC and ccfDNA levels on patient progression-free survival (PFS) and overall survival (OS) were analysed using Cox proportional hazards models. RESULTS: Compared to patients with <5 CTCs, patients with ≥5 CTCs had a 2.58-fold increased risk of progression and 3.63-fold increased risk of death. High level of ccfDNA was associated with a 2.05-fold increased risk of progression and 3.56-fold increased risk of death. These associations remained significant after adjusting for other important clinical covariates and CTC/ccfDNA levels. CTC and ccfDNA levels had a joint effect on patient outcomes. Compared to patients with low levels of both CTC and ccfDNA, those with high levels of both markers exhibited a >17-fold increased death risk (P < 0.001). Moreover, longitudinal analysis of 132 samples from 22 patients suggested that the inconsistency between CTC level and outcome in some patients could possibly be explained by ccfDNA level. CONCLUSIONS: CTC and total ccfDNA levels were individually and jointly associated with PFS and OS in MBC patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ye Z, Wang C, Wan S, et al. Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA. Eur J Cancer. 2018. PMID: 30528798. doi:10.1016/j.ejca.2018.10.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。